Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19326225 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | September 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19311629 | UROLITHIN GUMMY (PECTIN) FORMULATIONS | August 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19264750 | TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN | July 2025 | January 2026 | Allow | 6 | 1 | 0 | No | No |
| 19251149 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | June 2025 | September 2025 | Allow | 3 | 1 | 0 | No | No |
| 19243333 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | June 2025 | March 2026 | Allow | 9 | 1 | 0 | Yes | No |
| 19095550 | CANNABIS COMPOSITIONS, ORAL PRODUCTS, AND METHODS OF MAKING SAME | March 2025 | September 2025 | Allow | 6 | 2 | 0 | No | No |
| 19078590 | Adhering Lozenge with High Amount of Sparsely Soluble Active Ingredient | March 2025 | October 2025 | Allow | 8 | 1 | 0 | No | No |
| 19071625 | MICRONEEDLE ARRAY PATCHES (MAPS), SYSTEMS, AND METHODS FOR MANUFACTURING AND USING SAME | March 2025 | January 2026 | Allow | 10 | 1 | 0 | No | No |
| 19025220 | GELS FOR INSULIN DELIVERY | January 2025 | April 2025 | Allow | 3 | 1 | 0 | No | No |
| 19009331 | SUSPENSION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | January 2025 | October 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 19004850 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18986791 | DUAL ACTING POLYMERS IN AN OSMOTIC FILM FOR TOPICAL APPLICATION TO TREAT INFLAMMATORY DISEASES AND CYTOKINE RELEASE SYNDROME | December 2024 | November 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18975144 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | December 2024 | February 2025 | Allow | 2 | 1 | 0 | No | No |
| 18946268 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | November 2024 | November 2025 | Allow | 12 | 3 | 0 | No | No |
| 18911732 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | October 2024 | December 2024 | Allow | 2 | 1 | 0 | No | No |
| 18897657 | OPHTHALMIC FORMULATIONS AND METHODS OF USE | September 2024 | January 2025 | Allow | 4 | 1 | 0 | No | No |
| 18791632 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | August 2024 | October 2024 | Allow | 2 | 1 | 0 | No | No |
| 18789870 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | July 2024 | September 2024 | Allow | 2 | 1 | 0 | No | No |
| 18755045 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | June 2024 | August 2024 | Allow | 2 | 1 | 0 | No | No |
| 18667581 | TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN | May 2024 | April 2025 | Allow | 11 | 2 | 0 | No | No |
| 18664248 | CANNABIS COMPOSITIONS, ORAL PRODUCTS, AND METHODS OF MAKING SAME | May 2024 | December 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18654883 | Antibody Biopharmaceutical Formulations Including Polymer Excipients | May 2024 | July 2025 | Allow | 15 | 0 | 0 | No | No |
| 18643145 | Additive Compositions for Pigmented Disinfection and Methods Thereof | April 2024 | October 2025 | Allow | 17 | 1 | 0 | No | No |
| 18643422 | NERATINIB-CYCLODEXTRIN COMPOSITION AND METHOD FOR PREPARING SAME | April 2024 | February 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18633642 | PHARMACEUTICAL COMPOSITION FOR TREATING OR IMPROVING EDEMA AND BLOOD STASIS AFTER OPEN SURGERY | April 2024 | February 2025 | Allow | 10 | 1 | 0 | No | No |
| 18623901 | COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS | April 2024 | December 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18608675 | ADHESION PREVENTION WITH SHEAR-THINNING POLYMERIC HYDROGELS | March 2024 | December 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18588687 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | February 2024 | July 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18588996 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | February 2024 | September 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18588820 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | February 2024 | August 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18588892 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | February 2024 | August 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18588938 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | February 2024 | August 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18425208 | TUNABLE, CONTROLLED-RELEASE, URETHANE-CONTAINING ELASTOMERS AND PROCESSES OF FORMING THE SAME | January 2024 | February 2025 | Abandon | 13 | 0 | 1 | No | No |
| 18416293 | Encased Tamper Resistant Controlled Release Dosage Forms | January 2024 | June 2025 | Allow | 16 | 2 | 0 | No | No |
| 18415019 | TOPICAL SKIN COMPOSITIONS FOR TREATING WRINKLES | January 2024 | February 2026 | Abandon | 25 | 2 | 0 | No | No |
| 18411663 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | January 2024 | June 2024 | Allow | 5 | 1 | 0 | No | No |
| 18402042 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT | January 2024 | August 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18401652 | FRACTIONATED RADIOTHERAPY AND CHEMOTHERAPY WITH AN OXYGEN THERAPEUTIC | January 2024 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18397342 | POLYLACTIC ACID MICROSPHERE, POLYLACTIC-CO-GLYCOLIC ACID MICROSPHERE AND METHOD OF PREPARING THE SAME | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18395565 | COMPOSITIONS AND METHODS FOR MINIMIZING EFFECTS OF ALCOHOL INTOXICATION | December 2023 | August 2024 | Allow | 8 | 2 | 0 | No | No |
| 18539830 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT | December 2023 | June 2025 | Abandon | 18 | 2 | 1 | No | No |
| 18529137 | PHARMACEUTICAL COMPOSITION OF DILTIAZEM HYDROCHLORIDE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | December 2023 | April 2024 | Allow | 4 | 0 | 1 | No | No |
| 18519955 | NEBULIZATION FORMULATIONS FOR DELIVERY TO LOWER RESPIRATORY TRACT | November 2023 | March 2025 | Allow | 16 | 1 | 1 | No | No |
| 18488366 | TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18553141 | SUSPENSION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | September 2023 | November 2025 | Allow | 26 | 2 | 0 | No | No |
| 18472743 | METHODS FOR ORAL PAIN RELIEF | September 2023 | April 2024 | Allow | 6 | 0 | 0 | No | No |
| 18550802 | WATER-SOLUBLE TOPICAL OPHTHALMIC PREPARATION CONTAINING LUTEIN AND PRODUCTION METHOD THEREOF | September 2023 | February 2026 | Allow | 29 | 1 | 0 | No | No |
| 18460763 | Compositions for Enhancing Bioavailability of Pharmaceuticals, Supplements and Ingested Substances | September 2023 | June 2025 | Abandon | 21 | 4 | 0 | No | No |
| 18241523 | TOPICAL SKIN CREAM | September 2023 | December 2023 | Allow | 4 | 1 | 0 | No | No |
| 18241540 | TOPICAL SKIN CREAM | September 2023 | November 2023 | Allow | 2 | 1 | 0 | No | No |
| 18456759 | BORTEZOMIB COMPOSITIONS | August 2023 | April 2024 | Allow | 8 | 1 | 0 | No | No |
| 18547777 | URIDINE TRIACETATE AMORPHOUS FORMULATION | August 2023 | January 2026 | Allow | 28 | 2 | 0 | No | No |
| 18447553 | PHARMACEUTICAL COMPOSITIONS CONTAINING PSILOCYBIN FOR IMPROVED DISSOLUTION AND RAPID ONSET BY TARGETED STOMACH AND MUCOSAL RELEASE | August 2023 | February 2026 | Abandon | 30 | 0 | 1 | No | No |
| 18264938 | OPHTHALMIC COMPOSITIONS | August 2023 | December 2025 | Allow | 28 | 1 | 0 | No | No |
| 18226572 | THERAPEUTIC COMPOSITION INCLUDING PHENOLIC COMPOUNDS DERIVED FROM OPUNTIA LITTORALIS | July 2023 | March 2024 | Allow | 8 | 2 | 1 | No | No |
| 18356901 | HYDROGEL PRODRUG FOR TREATMENT | July 2023 | August 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18355964 | SOLID PREPARATION, METHOD FOR PRODUCING SOLID PREPARATION, AND METHOD FOR GENERATING HYDROGEN | July 2023 | May 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18222331 | BLEACH COMPOSITIONS | July 2023 | May 2024 | Allow | 10 | 1 | 0 | No | No |
| 18213048 | COSMETIC COMPOSITIONS AND USES THEREOF | June 2023 | August 2025 | Abandon | 26 | 3 | 1 | No | No |
| 18212471 | ANTIMICROBIAL SUPERABSORBENT COMPOSITIONS | June 2023 | October 2024 | Allow | 16 | 1 | 0 | No | No |
| 18208287 | VITAMIN COMPOSITION FOR ORAL ADMINISTRATION | June 2023 | February 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18327658 | HYDROGEL PRODRUG FOR TREATMENT | June 2023 | May 2024 | Allow | 11 | 1 | 0 | No | No |
| 18323747 | ACIDIC GLUCOSE-BASED HAIR CARE COMPOSITION | May 2023 | January 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18038628 | SOLID DISPERSION, PHARMACEUTICAL PREPARATIONS, PREPARATION METHOD, AND APPLICATION THEREOF | May 2023 | February 2026 | Allow | 33 | 1 | 0 | No | No |
| 18200958 | ANTIBODY BIOPHARMACEUTICAL FORMULATIONS INCLUDING POLYMER EXCIPIENTS | May 2023 | February 2024 | Allow | 8 | 1 | 1 | No | No |
| 18197787 | TOPICAL SKIN CREAM | May 2023 | November 2023 | Allow | 6 | 2 | 1 | No | No |
| 18317786 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT | May 2023 | November 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18196710 | MULTILAYER COMPOSITE MATERIAL | May 2023 | July 2025 | Allow | 26 | 1 | 1 | No | No |
| 18315590 | Implantable Medical Device for the Delivery of an Antipsychotic | May 2023 | December 2025 | Abandon | 31 | 0 | 1 | No | No |
| 18036025 | ORAL THIN FILM | May 2023 | December 2025 | Abandon | 31 | 1 | 0 | No | No |
| 18310549 | EXTENDED RELEASE PLASTIC FORMULATION | May 2023 | December 2023 | Allow | 8 | 1 | 0 | No | No |
| 18136012 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | April 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18131715 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | April 2023 | April 2024 | Allow | 13 | 1 | 0 | No | No |
| 18128705 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18192955 | 5HT AGONISTS FOR TREATING DISORDERS | March 2023 | June 2025 | Allow | 27 | 1 | 1 | No | No |
| 18192404 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | March 2023 | August 2025 | Allow | 29 | 2 | 0 | Yes | No |
| 18125106 | THERAPEUTIC COMPOSITION INCLUDING PHENOLIC COMPOUNDS DERIVED FROM OPUNTIA LITTORALIS | March 2023 | September 2023 | Allow | 5 | 1 | 1 | No | No |
| 18188384 | BORTEZOMIB COMPOSITIONS | March 2023 | July 2023 | Allow | 4 | 1 | 0 | No | No |
| 18122284 | COMPOSITION FOR PROMOTING DRUG RELEASE OF DRUG-DELIVERY LIPOSOMES | March 2023 | October 2025 | Allow | 31 | 1 | 0 | No | No |
| 18122416 | ZWITTERIONICALLY MODIFIED POLYMERS AND HYDROGELS | March 2023 | April 2025 | Allow | 25 | 0 | 1 | No | No |
| 18184470 | Gummy Composition for Relief from Hangover | March 2023 | January 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18025803 | CHEBULINIC ACID AND ITS ENRICHED FRACTION FROM THE FRUITS OF TERMINALIA CHEBULA FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) AND ITS PREPARATION THEREOF | March 2023 | February 2026 | Allow | 35 | 2 | 0 | No | No |
| 18175020 | Compositions for Enhancing Bioavailability of Pharmaceuticals, Supplements and Ingested Substances | February 2023 | September 2024 | Allow | 18 | 2 | 1 | No | No |
| 18175442 | MUCOADHESIVE COMPOSITIONS FOR DIRECTIONAL DELIVERY OF ACTIVE AGENTS | February 2023 | August 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18169571 | TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN | February 2023 | September 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 18109421 | FULVESTRANT FORMULATIONS AND METHODS OF THEIR USE | February 2023 | November 2024 | Allow | 21 | 2 | 0 | No | No |
| 18166416 | LYOPROTECTANT COMPOSITIONS AND USES THEREOF | February 2023 | July 2023 | Allow | 6 | 2 | 0 | Yes | No |
| 18007003 | PHARMACEUTICAL COMPOSITIONS FOR THE NASAL ADMINISTRATION OF A COBALAMIN COMPOUND | January 2023 | September 2023 | Allow | 8 | 1 | 0 | No | No |
| 18096686 | Encased Tamper Resistant Controlled Release Dosage Forms | January 2023 | October 2023 | Allow | 9 | 1 | 0 | No | No |
| 18153528 | Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile | January 2023 | January 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18015422 | METHOD AND SYSTEM FOR MANUFACTURING ORAL SOLUBLE FILMS, COMPOSITIONS OF ORAL SOLUBLE FILMS, ORAL SOLUBLE FILMS MADE BY THEREBY, AND METHODS OF USE THEREOF | January 2023 | November 2025 | Abandon | 34 | 3 | 1 | No | No |
| 18150292 | Compositions Containing Microcapsules | January 2023 | March 2025 | Allow | 26 | 3 | 0 | No | No |
| 18150152 | COMPOSITIONS AND METHODS FOR TREATING EOSINOPHILIC DISORDERS | January 2023 | December 2024 | Allow | 23 | 0 | 1 | No | No |
| 18148756 | Skincare Composition and Process for Creating Sulforaphane | December 2022 | February 2026 | Allow | 38 | 1 | 1 | No | No |
| 18146022 | BIOABSORBABLE POLYMERIC COMPOSITION FOR A MEDICAL DEVICE | December 2022 | July 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18145463 | PULLULAN CAPSULES | December 2022 | October 2023 | Allow | 9 | 1 | 0 | No | No |
| 18078921 | COMPOSITION FOR INCREASING SEXUAL DESIRE OR PLEASURE | December 2022 | October 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18063085 | IONTOPHORETIC MICRONEEDLE DEVICE | December 2022 | August 2025 | Abandon | 33 | 3 | 0 | No | No |
| 17994166 | FRACTIONATED RADIOTHERAPY AND CHEMOTHERAPY WITH AN OXYGEN THERAPEUTIC | November 2022 | September 2023 | Allow | 10 | 1 | 0 | No | No |
| 17925366 | ORGANIC SOL-GEL NANO-COMPOSITION FROM PANAX NOTOGINSENG, RUTIN, GINKGO BILOBA EFFECTIVE IN ENHANCING CEREBRAL AND CARDIOVASCULAR PROTECTION AND METHOD OF PRODUCING THEREOF | November 2022 | August 2025 | Allow | 33 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MERCIER, MELISSA S.
With a 47.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MERCIER, MELISSA S works in Art Unit 1615 and has examined 1,237 patent applications in our dataset. With an allowance rate of 67.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 28 months.
Examiner MERCIER, MELISSA S's allowance rate of 67.7% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MERCIER, MELISSA S receive 2.20 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MERCIER, MELISSA S is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -2.2% benefit to allowance rate for applications examined by MERCIER, MELISSA S. This interview benefit is in the 8% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 24.1% of applications are subsequently allowed. This success rate is in the 35% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 47.6% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 58.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 52.3% are granted (fully or in part). This grant rate is in the 52% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.6% of allowed cases (in the 78% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.4% of allowed cases (in the 70% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.